通过使用患者生物防护护理单元来管理实验室潜在的埃博拉病毒暴露风险。
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.
作者信息
Kortepeter Mark G, Martin James W, Rusnak Janice M, Cieslak Theodore J, Warfield Kelly L, Anderson Edwin L, Ranadive Manmohan V
机构信息
US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
出版信息
Emerg Infect Dis. 2008 Jun;14(6):881-7. doi: 10.3201/eid1406.071489.
Abstract
In 2004, a scientist from the US Army Medical Research Institute of Infectious Diseases (USAMRIID) was potentially exposed to a mouse-adapted variant of the Zaire species of Ebola virus. The circumstances surrounding the case are presented, in addition to an update on historical admissions to the medical containment suite at USAMRIID. Research facilities contemplating work with pathogens requiring Biosafety Level 4 laboratory precautions should be mindful of the occupational health issues highlighted in this article.
摘要
2004年，美国陆军传染病医学研究所（USAMRIID）的一名科学家可能接触到了扎伊尔埃博拉病毒的小鼠适应变种。除了对USAMRIID医疗隔离病房的历史收治情况进行更新外，还介绍了该病例的相关情况。考虑开展需要生物安全4级实验室防护措施的病原体研究工作的研究机构，应留意本文所强调的职业健康问题。
相似文献
1
Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.通过使用患者生物防护护理单元来管理实验室潜在的埃博拉病毒暴露风险。
Emerg Infect Dis. 2008 Jun;14(6):881-7. doi: 10.3201/eid1406.071489.
2
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.德国汉堡生物安全 4 级实验室中埃博拉病毒意外暴露的管理。
J Infect Dis. 2011 Nov;204 Suppl 3:S785-90. doi: 10.1093/infdis/jir298.
3
Channeling, high-level biocontainment and research.通道、高级生物安全防护与研究。
Ann Emerg Med. 2015 Feb;65(2):15A-22A. doi: 10.1016/j.annemergmed.2014.12.023.
4
Containment Care Units for Managing Patients With Highly Hazardous Infectious Diseases: A Concept Whose Time Has Come.用于管理高危险性传染病患者的隔离护理单元：一个时机已到的概念。
J Infect Dis. 2016 Oct 15;214(suppl 3):S137-S141. doi: 10.1093/infdis/jiw292. Epub 2016 Sep 19.
5
Perspectives on the Management of Children in a Biocontainment Unit: Report of the NETEC Pediatric Workgroup.生物隔离单位中儿童管理的观点：NETEC 儿科工作组的报告。
Health Secur. 2019 Jan/Feb;17(1):11-17. doi: 10.1089/hs.2018.0074.
6
Ebola virus disease. Recognizing the face of a rare killer.埃博拉病毒病。认清一种罕见杀手的真面目。
Postgrad Med. 1996 May;99(5):75-6, 78.
7
Ebola Virus Disease: Clinical Challenges, Recognition, and Management.埃博拉病毒病：临床挑战、识别与管理。
Nurs Clin North Am. 2019 Jun;54(2):169-180. doi: 10.1016/j.cnur.2019.02.001. Epub 2019 Mar 26.
8
Use of Postexposure Prophylaxis After Occupational Exposure to Zaire ebolavirus.职业性接触扎伊尔埃博拉病毒后使用暴露后预防措施。
Clin Infect Dis. 2016 Aug 1;63(3):376-9. doi: 10.1093/cid/ciw256. Epub 2016 Apr 26.
9
High-Containment Pathogen Preparation in the Intensive Care Unit.重症监护病房中的高致病性病原体制备
Infect Dis Clin North Am. 2017 Sep;31(3):561-576. doi: 10.1016/j.idc.2017.05.008.
10
Laboratory diagnosis of Ebola virus disease and corresponding biosafety considerations in the China Ebola Treatment Center.中国埃博拉治疗中心埃博拉病毒病的实验室诊断及相应的生物安全考虑。
Crit Rev Clin Lab Sci. 2016 Oct;53(5):326-40. doi: 10.3109/10408363.2016.1160866. Epub 2016 Apr 12.
引用本文的文献
1
Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development.马尔堡病毒病的治疗进展：从实验性治疗到疫苗研发
Ann Med Surg (Lond). 2025 Mar 28;87(5):2784-2799. doi: 10.1097/MS9.0000000000003213. eCollection 2025 May.
2
Biosafety Risk Control Strategies in Laboratory Animal Research.实验动物研究中的生物安全风险控制策略
Saf Health Work. 2024 Mar;15(1):118-122. doi: 10.1016/j.shaw.2023.11.005. Epub 2023 Nov 18.
3
A narrative review of high-level isolation unit operational and infrastructure features.高级隔离单元操作和基础设施特点的叙述性综述。
BMJ Glob Health. 2023 Jul;8(7). doi: 10.1136/bmjgh-2023-012037.
4
Multivariate analyses of risk factors associated with laboratory exposure incidents.与实验室暴露事件相关的危险因素的多变量分析。
Can Commun Dis Rep. 2022 Jul 7;48(7-8):350-355. doi: 10.14745/ccdr.v48i78a06.
5
Laboratory-acquired infections in Canada from 2016 to 2021.2016年至2021年加拿大的实验室获得性感染
Can Commun Dis Rep. 2022 Jul 7;48(7-8):303-307. doi: 10.14745/ccdr.v48i78a02.
6
A Brief History of Biocontainment.生物隔离简史
Curr Treat Options Infect Dis. 2016;8(4):251-258. doi: 10.1007/s40506-016-0096-2. Epub 2016 Oct 20.
7
Post-exposure prophylactic vaccine candidates for the treatment of human Risk Group 4 pathogen infections.用于治疗人类风险组4病原体感染的暴露后预防性候选疫苗。
Expert Rev Vaccines. 2020 Jan;19(1):85-103. doi: 10.1080/14760584.2020.1713756. Epub 2020 Jan 30.
8
Biosafety level-2 laboratory diagnosis of Zaire Ebola virus disease imported from Liberia to Nigeria.从利比里亚输入尼日利亚的扎伊尔埃博拉病毒病的生物安全二级实验室诊断
Afr J Lab Med. 2016 Oct 17;5(1):468. doi: 10.4102/ajlm.v5i1.468. eCollection 2016.
9
Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.使用基于羊抗体的治疗药物EBOTAb对豚鼠进行埃博拉病毒病暴露后治疗。
Sci Rep. 2016 Jul 28;6:30497. doi: 10.1038/srep30497.
10
Ebola Virus Shedding and Transmission: Review of Current Evidence.埃博拉病毒的脱落与传播：当前证据综述
J Infect Dis. 2016 Oct 15;214(suppl 3):S177-S184. doi: 10.1093/infdis/jiw254. Epub 2016 Jul 20.
本文引用的文献
1
Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement.设计用于护理严重传染病患者的生物安全隔离单元：一份共识声明。
Biosecur Bioterror. 2006;4(4):351-65. doi: 10.1089/bsp.2006.4.351.
2
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial.一种针对埃博拉病毒的DNA疫苗在I期临床试验中是安全且具有免疫原性的。
Clin Vaccine Immunol. 2006 Nov;13(11):1267-77. doi: 10.1128/CVI.00162-06. Epub 2006 Sep 20.
3
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.RNA干扰可使豚鼠在接触埃博拉病毒后获得针对致死性病毒攻击的保护。
J Infect Dis. 2006 Jun 15;193(12):1650-7. doi: 10.1086/504267. Epub 2006 May 10.
4
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.用编码修饰糖蛋白的单低剂量腺病毒载体对非人灵长类动物进行埃博拉病毒免疫保护。
PLoS Med. 2006 Jun;3(6):e177. doi: 10.1371/journal.pmed.0030177. Epub 2006 May 16.
5
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers.基于反义磷酰二胺吗啉代寡聚物的针对埃博拉病毒的基因特异性对策。
PLoS Pathog. 2006 Jan;2(1):e1. doi: 10.1371/journal.ppat.0020001. Epub 2006 Jan 13.
6
Antisense oligonucleotides: the state of the art.反义寡核苷酸：当前技术水平
Curr Med Chem. 2005;12(19):2193-214. doi: 10.2174/0929867054864859.
7
Biodefense labs. Boston University Under Fire for Pathogen Mishap.生物防御实验室。波士顿大学因病原体事故遭抨击。
Science. 2005 Jan 28;307(5709):501. doi: 10.1126/science.307.5709.501a.
8
Laboratory exposures to staphylococcal enterotoxin B.实验室接触葡萄球菌肠毒素B。
Emerg Infect Dis. 2004 Sep;10(9):1544-9. doi: 10.3201/eid1009.040250.
9
Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).美国陆军传染病医学研究所（USAMRIID）基于风险评估对潜在实验室暴露于生物恐怖主义制剂进行医学管理的经验。
J Occup Environ Med. 2004 Aug;46(8):801-11. doi: 10.1097/01.jom.0000135539.99691.4e.
10
Management guidelines for laboratory exposures to agents of bioterrorism.实验室接触生物恐怖主义制剂的管理指南。
J Occup Environ Med. 2004 Aug;46(8):791-800. doi: 10.1097/01.jom.0000135536.13097.8a.
Zotero 插件